K2-BioLabs offers “big company” resources that accommodate “small company” budgets Rapha Portfolio Company PONCE Therapeutics, Inc. is an investor and the first tenant of K2 Bio Houston, TX, June 14,...
Read More
Written By: Ben Adams, Senior Editor, FierceBiotechhttps://www.fiercebiotech.com/biotech/rapha-capital-management-launches-100m-life-science-vc-fund-eye-early-science Life science venture capital firm Rapha Capital Management has launched its first managed venture capital fund with a target raise of $100M and…
– Rapha Capital BioVentures (RCBV) Fund, with a target of $100M, builds on Rapha Capital’s successful history guiding the advancements of target biotech investments – – RCBV Fund plans to…
Rapha Capital Management (RCM LLC) Joined by Mendham Investment Group (MIG FZ LLC) in Leading the Financing FIZE’s Novel iUO™ Device Conquers the Last Frontier in Patient Monitoring Rapha Capital’s…
NexImmune Raises Gross Proceeds of $126.5M in Upsized IPO Legacy SPIVs Establish Rapha Capital’s Expertise in Identifying Disruptive Technologies MIAMI, Feb. 24, 2021 /PRNewswire/ — Rapha Capital Management, LLC (https://raphacap.com), an investment…
Rapha Capital Management Leads Convertible Note Financing Miami, FL – February 8, 2021 – Ponce Therapeutics, Inc. (“Ponce”), a company leveraging the growing scientific knowledge surrounding the aging process to…
Asclepix Therapeutics, Inc. AsclepiX Therapeutics, Inc. Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for Diabetic Macular Edema (DME) January 5, 2021
NexImmune Inc. NexImmune Strengthens Scientific Leadership by Appointing Jerome Zeldis as EVP R&D and Jeffrey Weber as Chief Scientific Advisor Zeldis formerly served as Celgene CMO and CEO of Celgene…
NexImmune Inc. Preliminary Results from NexImmune’s Phase 1/2 Trial of NEXI-001 in AML Presented at 62nd ASH Annual Meeting and Exposition Initial data demonstrate early signs of safety, tolerability and…
Poseida Therapeutics and Rapha Capital Management Rapha Capital Management Participates in Series D Financing for Poseida Therapeutics June 25, 2020